Gene therapies have made significant progress in the treatment of many diseases, including cancer, rare genetic diseases, and autoimmune disorders by replacing, adding, or turning off a patient’s genes. With the promise to enhance treatment, greatly reduce side effects, and potentially cure many types of diseases and disorders, these therapies are in high demand, and biopharma companies are in a race to the clinic.
The most common viral vectors include adeno associated (AAV), lenti, adeno, and retro viruses. These vectors are used to carry genetic material into host cells to replace missing or defective genes by direct delivery in vivo or modification of cells ex vivo for delivery back into a patient.
Eurofins BioPharma Product Testing’s network of laboratories supports the development of Advanced Therapy Medicinal Products (ATMPs) both for traditional use as well as for use in personalized medicine. We provide comprehensive GMP-compliant CMC testing support to ensure the identity, potency, purity, and safety of starting materials, intermediate products, vectors, and final drug products as well as support for manufacturing process development and validation.